tiprankstipranks
Trending News
More News >
Masimo Corp (MASI)
NASDAQ:MASI
Advertisement

Masimo (MASI) AI Stock Analysis

Compare
1,223 Followers

Top Page

MASI

Masimo

(NASDAQ:MASI)

Rating:54Neutral
Price Target:
$157.00
▲(6.66% Upside)
Masimo's overall stock score is primarily impacted by its financial challenges and bearish technical indicators. However, strong earnings call highlights and strategic corporate events provide some positive outlook.
Positive Factors
Financial Performance
MASI's 2Q25 revenue and EPS beat consensus.
Management Strategies
Management highlighted the company's strong free cash flow generation capabilities, noting the potential for tuck-in M&A as appropriate.
Negative Factors
Legal Challenges
Masimo's patent infringement complaint against Apple in the Central District of California is set to begin a jury trial.
Tariff Impact
Tariffs will result in a significant headwind to cost of goods sold.

Masimo (MASI) vs. SPDR S&P 500 ETF (SPY)

Masimo Business Overview & Revenue Model

Company DescriptionMasimo Corporation develops, manufactures, and markets noninvasive monitoring technologies and hospital automation solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry. It also provides Masimo rainbow SET platform that includes rainbow SET Pulse CO-Oximetry products that noninvasively monitor hemoglobin species, including oxygen saturation, pulse rate, perfusion index, pleth variability index, and respiration rate from the pleth; noninvasively monitor hemoglobin concentration, and carboxyhemoglobin and methemoglobin; monitor arterial oxygen saturation and acoustic respiration rate; and calculates oxygen content and oxygen reserve index. It offers SedLine brain function monitoring technology to measure the brain's electrical activity by detecting EEG signals; capnography and gas monitoring products comprising external plug-in-and-measure capnography and gas analyzers, integrated modules, handheld capnograph and capnometer devices, and capnography sampling lines; O3 regional oximetry for tissue oxygen saturation measurement; and hemodynamic monitoring solutions. Its Masimo Hospital Automation platform includes Patient SafetyNet, Patient SafetyNet surveillance, Kite, UniView, Replica, UniView : 60, and MyView. It offers connectivity devices; and nasal high flow ventilation and neuromodulation solutions. It provides its products through direct sales force, distributors, and original equipment manufacturers partners to hospitals, emergency medical service and home care providers, long-term care facilities, physician offices, veterinarians, and consumers; and non-medical/consumer products through e-commerce site, masimopersonalhealth.com. The company was incorporated in 1989 and is headquartered in Irvine, California.
How the Company Makes MoneyMasimo generates revenue primarily through the sale of its medical devices and accessories, as well as through recurring revenue from product disposables and software subscriptions. The company has a diverse range of revenue streams, including direct sales to hospitals, healthcare systems, and distributors. Key revenue components include the sale of pulse oximeters, sensors, and other monitoring devices, which are often sold alongside consumable products that require replenishment. Significant partnerships with healthcare organizations and integration of its technologies into electronic medical record systems further enhance its revenue potential. Additionally, Masimo's commitment to research and development allows it to continuously innovate, introducing new products and solutions that contribute to its earnings.

Masimo Earnings Call Summary

Earnings Call Date:Aug 05, 2025
(Q2-2025)
|
% Change Since: |
Next Earnings Date:Nov 11, 2025
Earnings Call Sentiment Positive
The earnings call highlighted strong revenue growth and significant leadership team expansion, with effective tariff mitigation strategies. However, there were challenges with a decline in capital equipment revenue, cybersecurity expenses, and a decrease in the true incremental metric. Overall, the highlights significantly outweigh the lowlights.
Q2-2025 Updates
Positive Updates
Strong Revenue and Earnings Performance
The core Healthcare business delivered revenue of $370 million and earnings per share of $1.33, with 600 basis points of operating margin expansion.
Leadership Team Expansion
Masimo added several key leaders, including a Chief Commercial Officer, President of Japan and Asia Pacific, Chief Marketing and Strategy Officer, Executive Vice President of Quality and Regulatory, and Chief Information Technology Officer.
EPS Guidance Exceeds Original Projections
Despite the impact of tariffs, Masimo projects 24% to 30% EPS growth this year, exceeding original projections before tariffs.
Tariff Mitigation Success
The company reduced the tariff impact by more than 50% from the original estimate through effective mitigation measures.
Intelligent Monitoring and Wearable Technologies
Masimo focuses on accelerating intelligent monitoring with AI-based algorithms and innovating wearable technologies to expand long-term growth potential.
Negative Updates
Decline in Capital Equipment and Other Revenue
Capital equipment and other revenue declined by 2% due to a transition from capital lease to operating lease accounting.
Cybersecurity Event and Related Expenses
The company incurred approximately $4.5 million in net expenses to recover and fortify systems after a cybersecurity event.
Challenges with True Incremental Metric
The true incremental metric was down over 20% in Q1 and 40% in Q2, attributed to the timing of large deals.
Company Guidance
During Masimo's second quarter 2025 earnings call, the company reported strong financial performance and provided updated guidance. Revenue for the quarter was $370 million, with earnings per share (EPS) reaching $1.33, and an impressive 600 basis points of operating margin expansion. Despite facing tariffs, the company projects a 24% to 30% EPS growth for the year, and has successfully reduced its tariff impact by more than 50% from initial estimates. Masimo updated its fiscal 2025 financial guidance, projecting revenue between $1.505 billion and $1.535 billion, reflecting constant currency growth of 8% to 11%. Non-GAAP EPS guidance was adjusted to a range of $5.20 to $5.45, incorporating the impact of tariffs. The company highlighted its strategic focus on elevating commercial excellence, accelerating intelligent monitoring, and innovating wearable technologies to drive long-term growth.

Masimo Financial Statement Overview

Summary
Masimo faces significant financial challenges with declining revenue and profitability, negative margins, and increasing leverage. However, positive free cash flow growth provides some resilience.
Income Statement
45
Neutral
Masimo's income statement shows a concerning trend with declining revenue and profitability. The TTM data indicates a negative revenue growth rate of -6.35%, and the net profit margin has turned negative at -25.06%. The gross profit margin remains moderate at 50.50%, but the company is experiencing operational challenges, as evidenced by negative EBIT and EBITDA margins. This suggests significant pressure on profitability and cost management.
Balance Sheet
55
Neutral
The balance sheet reflects moderate leverage with a debt-to-equity ratio of 0.72, which is manageable but has increased over time. The return on equity is negative at -40.95%, indicating that the company is not generating returns for shareholders. The equity ratio stands at 43.40%, showing a reasonable level of equity financing. However, the declining equity and increasing debt levels pose potential risks.
Cash Flow
60
Neutral
Masimo's cash flow statement shows some resilience with a positive free cash flow growth rate of 3.24% in the TTM period. The operating cash flow to net income ratio is 0.33, indicating that cash flows are still being generated despite net losses. The free cash flow to net income ratio is 0.80, suggesting that the company is managing to convert a portion of its earnings into cash. However, the overall cash flow position needs improvement to support long-term sustainability.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue1.85B2.09B2.05B2.04B1.24B1.14B
Gross Profit975.20M1.00B1.00B1.06B808.40M743.00M
EBITDA-89.20M-158.70M236.70M355.20M310.30M293.30M
Net Income-459.20M-304.90M81.50M143.50M229.60M240.30M
Balance Sheet
Total Assets2.40B2.63B3.04B3.21B1.89B1.71B
Cash, Cash Equivalents and Short-Term Investments149.60M177.60M163.00M202.90M745.30M641.45M
Total Debt642.20M846.10M970.00M1.03B32.70M34.35M
Total Liabilities1.36B1.57B1.68B1.87B336.80M304.91M
Stockholders Equity1.04B1.05B1.36B1.34B1.55B1.41B
Cash Flow
Free Cash Flow148.40M176.40M6.40M-26.80M229.82M131.01M
Operating Cash Flow176.60M196.40M94.10M29.50M264.75M210.96M
Investing Cash Flow-28.50M-51.20M-81.20M-1.06B-37.53M-82.79M
Financing Cash Flow-95.80M-125.60M-57.10M520.30M-122.40M-54.31M

Masimo Technical Analysis

Technical Analysis Sentiment
Negative
Last Price147.19
Price Trends
50DMA
155.40
Negative
100DMA
157.53
Negative
200DMA
164.28
Negative
Market Momentum
MACD
-4.49
Positive
RSI
43.61
Neutral
STOCH
26.90
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MASI, the sentiment is Negative. The current price of 147.19 is above the 20-day moving average (MA) of 145.86, below the 50-day MA of 155.40, and below the 200-day MA of 164.28, indicating a bearish trend. The MACD of -4.49 indicates Positive momentum. The RSI at 43.61 is Neutral, neither overbought nor oversold. The STOCH value of 26.90 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for MASI.

Masimo Risk Analysis

Masimo disclosed 69 risk factors in its most recent earnings report. Masimo reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Masimo Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
79
Outperform
$5.37B45.778.60%10.14%0.04%
75
Outperform
$14.82B27.4811.38%1.28%-17.73%
73
Outperform
$5.70B29.674.36%1.05%1.11%-23.73%
71
Outperform
$9.12B23.3215.36%1.30%1.51%21.70%
68
Neutral
$2.61B16.5118.27%0.91%45.81%
54
Neutral
$7.48B116.65-20.54%-8.36%-669.36%
51
Neutral
$7.91B-0.36-41.71%2.23%23.45%-1.86%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
MASI
Masimo
147.19
35.66
31.97%
ATR
AptarGroup
138.46
-12.20
-8.10%
HAE
Haemonetics
54.08
-19.16
-26.16%
HOLX
Hologic
66.76
-14.81
-18.16%
MMSI
Merit Medical Systems
92.97
-3.61
-3.74%
TFX
Teleflex
130.70
-111.46
-46.03%

Masimo Corporate Events

Executive/Board Changes
Masimo Board Member William Jellison Resigns
Neutral
Aug 19, 2025

On August 18, 2025, William Jellison resigned from the Board of Directors of Masimo Corporation, with no disagreements cited regarding company operations. The Chairman of the Board, Michelle Brennan, expressed gratitude for his contributions during a transformative period for the company.

Business Operations and StrategyFinancial Disclosures
Masimo Reports Strong Q2 2025 Financial Results
Positive
Aug 5, 2025

On August 5, 2025, Masimo Corporation announced its financial results for the second quarter of 2025, reporting a GAAP revenue of $371 million, an 8% growth, and a non-GAAP revenue of $370 million, a 7% growth on a constant currency basis. The company’s non-GAAP net income per diluted share grew by 46% compared to the previous year. CEO Katie Szyman highlighted the company’s strong performance and strategic focus on expanding its leadership in pulse oximetry and implementing effective tariff mitigation measures, which have positively impacted its growth strategy and market position.

Executive/Board ChangesBusiness Operations and Strategy
Masimo Announces Key Leadership Changes in June 2025
Neutral
Jun 12, 2025

Masimo Corporation has made strategic leadership changes to enhance its commercial operations, appointing Tim Benner as Chief Marketing and Strategy Officer, Huimin Wang as President of Japan & Asia Pacific, and Lisa Hellmann as Chief Human Resources Officer in 2025. Additionally, Micah Young has expanded his role to include corporate development. The company is also seeking a Chief Commercial Officer. Meanwhile, Chief Operating Officer Bilal Muhsin announced his resignation effective July 1, 2025, and the company will not fill the COO role immediately.

Legal ProceedingsBusiness Operations and StrategyRegulatory Filings and Compliance
Masimo Addresses Cybersecurity Incident Risks
Negative
May 27, 2025

Masimo Corporation plans to engage with investors to reaffirm its financial outlook for fiscal 2025, as initially provided on May 6, 2025. The company is addressing a cybersecurity incident that may impact its operations, with potential legal, reputational, and financial risks, as well as possible regulatory inquiries and business disruptions.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Aug 19, 2025